Portal Hypertension Clinical Trial
Official title:
Cera™ Vascular Plug System Post-Market Clinical Follow-Up: A Multi-center, Prospective, Observational, Single-arm, Open-label, Post-market Study
The objective of the study is to collect and evaluate clinical data on patients of the Lifetech Cera™ Vascular Plug System to: - confirm the performance - confirm the safety - identify previously unknown side-effects - monitor the identified side-effects (related to the procedures or to the medical devices) - identify and analyse emergent risks
Status | Not yet recruiting |
Enrollment | 132 |
Est. completion date | June 2026 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Aged 18 to 85; 2. Life expectancy > 1 year; 3. Require arterial or venous embolization in the peripheral vasculature; 4. Target embolization site(s) allow for safe insertion of the delivery catheter; 5. Voluntarily sign and date the Informed Consent Form (ICF) prior to any study-related activities commencement; 6. Willing and able to comply with protocol requirements, including all study visits and procedures. Exclusion Criteria: 1. The subject is pregnant or plan to be pregnant or breast feeding; 2. The subject has a known allergy or hypersensitivity to any of the device materials including: nickel, stainless steel, polytetrafluoroethylene and titanium nitride; 3. The subject has a known allergy or hypersensitivity to contrast agent; 4. The subject has uncorrectable coagulopathy; 5. The subject has planned use of anticoagulant (e.g. direct thrombin inhibitors, factor Xa inhibitors, vitamin K antagonists) or antiplatelet therapy before, during and/or after treatment with the study device, which, in the opinion of the Investigator, would clinically interfere with the study endpoints 6. The subject has an unresolved systemic infection; 7. Subject who cannot tolerate general or local anesthesia; 8. The subject has a connective tissue disorders (e.g. Ehlers-Danlos Syndrome), arteritis (e.g. Takayasu's Disease) or another circulatory disorder; 9. The subject is participating in other drug or medical device clinical trials; 10. Any condition (medical or anatomic) making the subject not suitable for transcatheter embolotherapy according to the opinion of the investigator. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Lifetech Scientific (Shenzhen) Co., Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Technical success | Complete occlusion of the target embolization site at the time of the procedure. A target embolization site is considered completely occluded if angiography showed no residual flow. | at procedure | |
Secondary | Incidence of clinically relevant recanalization | Clinically relevant recanalization is defined as recanalization through the study device that requires a re-intervention. | at 3 months, 6 months, and 12 months post-procedure | |
Secondary | Incidence of clinically relevant migration | Clinically relevant migration is defined as migration of the study device from the target embolization site that requires a re-intervention. | at 3 months, 6 months, and 12 months post-procedure | |
Secondary | Incidence of device and/or procedure-related Adverse Events (AEs) | from attempted procedure to 12 months post-procedure | ||
Secondary | Incidence of device and/or procedure-related Serious Adverse Events (SAEs) | from attempted procedure to 12 months post-procedure | ||
Secondary | Incidence of device deficiencies | Device deficiency means any inadequacy in the identity, quality, durability, reliability, safety or performance of an investigational device, including malfunction, use errors or inadequacy in the information supplied by the manufacturer. | from attempted procedure to 12 months post-procedure | |
Secondary | Time to occlusion | Defined as the time from the device placement to complete occlusion of the target embolization sites. | at procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05052892 -
A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105)
|
||
Recruiting |
NCT05251272 -
A Combined Model Based on Spleen Stiffness, Liver Stiffness and Platelets for Assessing Portal Hypertension in Compensated Cirrhosis (CHESS2202)
|
||
Recruiting |
NCT05928624 -
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
|
N/A | |
Recruiting |
NCT04578301 -
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
|
||
Not yet recruiting |
NCT05515861 -
Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices
|
N/A | |
Recruiting |
NCT02364297 -
TIPS in Fundal Variceal Bleeding (the TFB Study)
|
N/A | |
Recruiting |
NCT01358123 -
Value of Von Willebrand Factor in Portal Hypertension
|
N/A | |
Completed |
NCT00493480 -
Danish Carvedilol Study in Portal Hypertension
|
Phase 3 | |
Recruiting |
NCT06266260 -
Evaluation of the Performance of Direct Portal Pressure Measurement by Endoscopic Ultrasound in a Large Cohort of Patients With Advanced Chronic Liver Disease of Different Etiologies and Newly Diagnosed Clinically Significant Portal Hypertension (EVADIPP)
|
||
Recruiting |
NCT03277651 -
Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension
|
N/A | |
Active, not recruiting |
NCT03736265 -
Carvedilol for Prevention of Esophageal Varices Progression
|
N/A | |
Completed |
NCT03451149 -
Feasibility And Safety Of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation Using A Radiofrequency Guidewire
|
N/A | |
Completed |
NCT02994485 -
Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin
|
Phase 4 | |
Completed |
NCT01851252 -
MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy
|
Phase 1 | |
Completed |
NCT01923064 -
Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices
|
N/A | |
Completed |
NCT01551966 -
Esophageal Capsule Endoscopy in Children
|
N/A | |
Completed |
NCT01456286 -
Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension
|
Phase 2/Phase 3 | |
Completed |
NCT02344719 -
Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis
|
Phase 4 | |
Recruiting |
NCT00414713 -
Transfusion Requirements in Gastrointestinal (GI) Bleeding
|
Phase 4 | |
Completed |
NCT00766805 -
Endoscopic Variceal Ligation (EVL)+ Drugs Versus Endoscopic Variceal Ligation (EVL) Alone For Secondary Prophylaxis
|
N/A |